- Home
- DTSS vs LYRA Comparison
DTSS vs LYRA Comparison
Compare DTSS & LYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DTSS
- LYRA
- Stock Information
- Founded
- DTSS 2014
- LYRA 2005
- Country
- DTSS China
- LYRA United States
- Employees
- DTSS N/A
- LYRA N/A
- Industry
- DTSS Computer Software: Prepackaged Software
- LYRA Medical/Dental Instruments
- Sector
- DTSS Technology
- LYRA Health Care
- Exchange
- DTSS Nasdaq
- LYRA Nasdaq
- Market Cap
- DTSS 16.5M
- LYRA 15.0M
- IPO Year
- DTSS N/A
- LYRA 2020
- Fundamental
- Price
- DTSS $1.96
- LYRA $6.58
- Analyst Decision
- DTSS
- LYRA Buy
- Analyst Count
- DTSS 0
- LYRA 2
- Target Price
- DTSS N/A
- LYRA $16.00
- AVG Volume (30 Days)
- DTSS 55.1K
- LYRA 37.8K
- Earning Date
- DTSS 09-25-2025
- LYRA 08-13-2025
- Dividend Yield
- DTSS N/A
- LYRA N/A
- EPS Growth
- DTSS N/A
- LYRA N/A
- EPS
- DTSS N/A
- LYRA N/A
- Revenue
- DTSS $56,255,129.00
- LYRA $1,185,000.00
- Revenue This Year
- DTSS N/A
- LYRA N/A
- Revenue Next Year
- DTSS N/A
- LYRA $139.18
- P/E Ratio
- DTSS N/A
- LYRA N/A
- Revenue Growth
- DTSS 144.20
- LYRA N/A
- 52 Week Low
- DTSS $1.63
- LYRA $3.81
- 52 Week High
- DTSS $3.55
- LYRA $37.50
- Technical
- Relative Strength Index (RSI)
- DTSS 43.05
- LYRA 33.89
- Support Level
- DTSS $1.91
- LYRA $7.77
- Resistance Level
- DTSS $2.17
- LYRA $8.37
- Average True Range (ATR)
- DTSS 0.11
- LYRA 0.54
- MACD
- DTSS -0.01
- LYRA -0.10
- Stochastic Oscillator
- DTSS 18.06
- LYRA 10.48
About DTSS Datasea Inc.
Datasea Inc is a technology company. Its offers provides acoustic business services (focusing on high-tech acoustic technologies and applications such as ultrasound, infrasound, and Schumann resonance), 5G application services (5G AI multimodal digital business), and other products and services to various corporate and individual customers. The business activity of the group functions through China.
About LYRA Lyra Therapeutics Inc.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.